Setrusumab
As of the edition of 20 October 2026, Setrusumab is an antibody: in active development; acts on SOST.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2027
- Kind
- Antibody
- Registered trials
- 10, 3 stopped early
- Disease areas
- Bones, joints and muscles; Inherited and neonatal; Skin and connective tissue; Nutrition and metabolism; Injuries
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SOST | Sclerostin | Q9BQB4 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 7 | 4 | 0 | 3 |
| Phase 3 | 3 | 0 | 3 | 0 |
| All trials | 10 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Ultragenyx Pharmaceutical | Lead sponsor of trials | 2011 to now |